Xesai / iStockphoto.com
19 July 2018Americas
Sanofi in $50m oncology collaboration
Sanofi has partnered with biotechnology company Revolution Medicines to develop treatments for multiple cancers.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019 Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.
Editor's picks
Editor's picks
Big Pharma
23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019 Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.
Big Pharma
23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019 Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.